Pharmaceutical companies are likely to continue to have unpronounceable names for the foreseeable future, according to researchers. ‘A cure won’t happen soon,’ said a spokesman for Pfizer which is making a bid for AstraZenec – or whatever they are called. ‘It’s still a distant prospect.’
Meanwhile a spokesman for GlaxoSmithKline claimed to have made some progress in discovering a pronounceable – if ungrammatical – name for a pharmaceutical company.
But French pharmaceutical Sanofi-Aventis said that the prospect of a Pfizer-AstraZenec company would create a new strain of the problem. ‘Most people can’t even pronounce ‘pharmaceutical’, a Sanofi-Aventis spokesman said. ‘ Or even ‘company.’